These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
159 related items for PubMed ID: 14669827
1. Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis. Nascif SO, Senger MH, Ramos-Dias JC, Lengyel AM. J Endocrinol Invest; 2003 Aug; 26(8):733-7. PubMed ID: 14669827 [Abstract] [Full Text] [Related]
2. Iopanoic acid-induced decrease of circulating T3 causes a significant increase in GH responsiveness to GH releasing hormone in thyrotoxic patients. Ramos-Dias JC, Lengyel AM. Clin Endocrinol (Oxf); 1999 Oct; 51(4):461-7. PubMed ID: 10583313 [Abstract] [Full Text] [Related]
4. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus. Micić D, Macut D, Popović V, Kendereski A, Sumarac-Dumanović M, Zorić S, Dieguez C, Casanueva FF. Metabolism; 1999 Apr; 48(4):525-30. PubMed ID: 10206449 [Abstract] [Full Text] [Related]
5. Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH. Nascif SO, Correa-Silva SR, Silva MR, Lengyel AM. Pituitary; 2007 Apr; 10(1):27-33. PubMed ID: 17410412 [Abstract] [Full Text] [Related]
6. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients. Cordido F, Alvarez-Castro P, Isidro ML, Casanueva FF, Dieguez C. Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288 [Abstract] [Full Text] [Related]
7. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. Catalina PF, Mallo F, Andrade MA, García-Mayor RV, Diéguez C. J Clin Endocrinol Metab; 1998 Oct; 83(10):3663-7. PubMed ID: 9768681 [Abstract] [Full Text] [Related]
8. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. Van Dam PS, Smid HE, de Vries WR, Niesink M, Bolscher E, Waasdorp EJ, Dieguez C, Casanueva FF, Koppeschaar HP. J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132 [Abstract] [Full Text] [Related]
9. Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment. Molica P, Nascif SO, Correa-Silva SR, de Sá LB, Vieira JG, Lengyel AM. Pituitary; 2010 Dec; 13(4):315-23. PubMed ID: 20602173 [Abstract] [Full Text] [Related]
11. Different growth hormone (GH) response to GH-releasing peptide and GH-releasing hormone in hyperthyroidism. Ramos-Dias JC, Pimentel-Filho F, Reis AF, Lengyel AM. J Clin Endocrinol Metab; 1996 Apr; 81(4):1343-6. PubMed ID: 8636330 [Abstract] [Full Text] [Related]
12. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. Cordido F, Peino R, Peñalva A, Alvarez CV, Casanueva FF, Dieguez C. J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550 [Abstract] [Full Text] [Related]
13. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854 [Abstract] [Full Text] [Related]
14. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus. Villas-Boas Weffort RF, Ramos-Dias JC, Chipoch C, Lengyel AM. Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309 [Abstract] [Full Text] [Related]
16. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness. Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R. Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573 [Abstract] [Full Text] [Related]
17. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy. Popovic V, Simic M, Ilic L, Micic D, Damjanovic S, Djurovic M, Obradovic S, Dieguez C, Casanueva F. Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075 [Abstract] [Full Text] [Related]
18. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Bowers CY, Granda-Ayala R. Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505 [Abstract] [Full Text] [Related]
19. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Popovic V, Leal A, Micic D, Koppeschaar HP, Torres E, Paramo C, Obradovic S, Dieguez C, Casanueva FF. Lancet; 2000 Sep 30; 356(9236):1137-42. PubMed ID: 11030292 [Abstract] [Full Text] [Related]